2-[2H-(1-甲基-1,3-二氢异吲哚)甲基]-4,5-二氢咪唑马来酸盐 | 118343-19-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-[2H-(1-甲基-1,3-二氢异吲哚)甲基]-4,5-二氢咪唑马来酸盐
• 英文名称: 2-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2,3-dihydro-1-methyl-1H-isoindole
• 英文别名: 2-(4,5-dihydro-1H-imidazol-2-ylmethyl)-1-methyl-1,3-dihydroisoindole
• CAS: 118343-19-4
• 化学式: C₁₃H₁₇N₃
• 分子量: 215.29
• InChiKey: SGOFAUSEYBZKDQ-UHFFFAOYSA-N

物化性质

• 沸点：
  365.8±30.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 溶解度：
  H2O：26 mg/mL，可溶
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，也未有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Combination treatment for sleep disorders including sleep apnea
  申请人：Pfizer Inc.

  公开号：US20020183306A1

  公开（公告）日：2002-12-05

  The present invention relates to a method of treating sleep disorders including sleep apnea in a mammal, including a human, by administering to the mammal a 5HT1a antagonist or an alpha-2-adrenergic antagonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1a antagonist or an alpha-2-adrenergic antagonist, and an SRI antidepressant agent.

  本发明涉及一种治疗哺乳动物（包括人类）的睡眠障碍，包括睡眠呼吸暂停的方法，通过给哺乳动物（包括人类）施用5HT1a拮抗剂或α-2肾上腺素受体拮抗剂与SRI抗抑郁药物的联合使用，以提高疗效。本发明还涉及含有药用载体、5HT1a拮抗剂或α-2肾上腺素受体拮抗剂和SRI抗抑郁药物的制药组合物。
• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Kõster Hubert

  公开号：US20100248264A1

  公开（公告）日：2010-09-30

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

  提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
• Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord disorders
  申请人：Ecole Polytechnique Fédérale de Lausanne (EPFL)

  公开号：EP2821072A1

  公开（公告）日：2015-01-07

  The invention relates to the selective targeting of specific α2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the α2c receptor subtype using an α2c specific agonist or by blocking the α2a receptor subtype using α2a antagonists. A combination of an α2c agonist and an α2a antagonist is also provided for a synergistic effect. Alternatively, an unspecific α2 agonist can be used in combination with an α2a antagonist to achieve specific stimulation of the α2c receptor. Pharmaceutical compositions and kit-of-parts comprising said agonists/antagonists as active agents are objects of the present invention. A robotic interface and epidural electric stimulation can also be used in combination with the compositions of the invention for restoring voluntary control of locomotion.

  本发明涉及选择性靶向特定α2肾上腺素能受体亚型，以促进和恢复受脊髓疾病（尤其是脊髓损伤）影响的患者的站立和行走。特别是，通过使用α2c特异性激动剂刺激α2c受体亚型，或使用α2a拮抗剂阻断α2a受体亚型，可针对特定受体亚型改善运动能力。α2c激动剂和α2a拮抗剂的组合也可产生协同效应。另外，非特异性的 α2 激动剂也可与α2a 拮抗剂结合使用，以实现对 α2c 受体的特异性刺激。包含上述激动剂/拮抗剂作为活性剂的药物组合物和部件包是本发明的目的。机器人接口和硬膜外电刺激也可与本发明的组合物结合使用，以恢复对运动的自主控制。
• Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord motor disorders
  申请人：ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

  公开号：US10632105B2

  公开（公告）日：2020-04-28

  The invention relates to the selective targeting of specific α2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the α2c receptor subtype using an α2c specific agonist or by blocking the α2a receptor subtype using α2a antagonists. A combination of an α2c agonist and an α2a antagonist is also provided for a synergistic effect. Alternatively, a large α2 agonist can be used in combination with an α2a antagonist to achieve specific stimulation of the α2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists/antagonists as active agents are objects of the present invention. A robotic interface and epidural electric stimulation can also be used in combination with the compositions of the invention for restoring voluntary control of locomotion.

  本发明涉及选择性靶向特定α2肾上腺素能受体亚型，以促进和恢复受脊髓疾病（尤其是脊髓损伤）影响的患者的站立和行走。特别是，通过使用α2c特异性激动剂刺激α2c受体亚型，或使用α2a拮抗剂阻断α2a受体亚型，可针对特定受体亚型改善运动能力。α2c受体激动剂和α2a受体拮抗剂的组合也可产生协同效应。另外，也可将一种大型 α2 激动剂与 α2a 拮抗剂结合使用，以实现对 α2c 受体的特异性刺激。包含上述激动剂/拮抗剂作为活性剂的药物组合物、部件包和治疗系统是本发明的目的。机器人接口和硬膜外电刺激也可与本发明的组合物结合使用，以恢复对运动的自主控制。
• Dueling bandits algorithm for neuromodulation therapy
  申请人：California Institute of Technology

  公开号：US10821285B2

  公开（公告）日：2020-11-03

  A system, method, and apparatus for identifying optimal or near optimal complex stimulation waveforms for a neurostimulator device or neuromodulation device are disclosed. An example method includes using a dueling bandits algorithm with correlation among stimulation arms to select a batch of stimulation arms for sequential application to a patient during a therapy session. Each of the stimulation arms specifies complex stimulation waveform parameter values. Feedback from applying the stimulation arms to the patient is recorded and used to update feedback reward values corresponding to at least some of the stimulation arms using a stimulation arm correlation index. A second batch of stimulations arms is selected based upon the updated feedback reward values and applied to a patient. The method is iteratively repeated over a number of therapy sessions until an optimal or near optimal batch of stimulation arms (defining complex stimulation waveforms) is determined.

  本发明公开了一种用于识别神经刺激器设备或神经调控设备的最佳或接近最佳复合刺激波形的系统、方法和装置。一种示例方法包括使用刺激臂之间具有相关性的决斗匪帮算法，选择一批刺激臂，以便在治疗过程中按顺序应用于患者。每个刺激臂指定复杂的刺激波形参数值。记录对患者施加刺激臂后得到的反馈，并利用刺激臂相关指数更新与至少部分刺激臂相对应的反馈奖励值。根据更新后的反馈奖励值选择第二批刺激臂并应用于患者。该方法在多次治疗过程中反复进行，直到确定最佳或接近最佳的一批刺激臂（定义复杂刺激波形）。